Back

Proteomic characterization of human coronary artery reveals different pathological stages of atherosclerosis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Chronic coronary syndromes: residual and non-traditional risk Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Xinjie Xu

Beijing (China)

7 More presentations in this session

Presentation thumbnail
Clinical characteristics and predictors of mortality in patients with refractory angina due to obstructive and non-obstructive chronic coronary syndromes: a contemporary retrospective cohort study.
Doctor K. Cheng (London, GB)
Abstract Slides Video
Presentation thumbnail
Exploring residual cardiovascular risk beyond LDL cholesterol in patients with acute destabilisation of known significant atherosclerosis
Doctor L. Bavuso (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Biological age as a new risk factor for myocardial Infarction?
Miss I. Nemere (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Chest pain and cardiac troponin flat curve: six-month prognosis of a cohort of patients
Doctor P. Awamleh Garcia (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Natural history of premature coronary artery disease : impact of residual atherosclerosis on long-term prognosis
Doctor G. Rahoual (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic coronary syndromes: residual and non-traditional risk

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
De-differentiation of synthetic vascular smooth muscle in human coronary artery plaque fibrous cap to macrophage-like vascular smooth muscle promotes plaque instability
thumbnail
Congress Presentation
Profiling the L-arginine/arginase 1 metabolism in early and advanced atherosclerosis
thumbnail
Congress Presentation
Integrated multi-omics predictive analysis of atherosclerosis: a sub-study from the Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources